Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Antiemetics
/ therapeutic use
Antineoplastic Agents
/ adverse effects
Cytochrome P-450 Enzyme System
/ drug effects
Humans
Nausea
/ chemically induced
Neoplasms
/ drug therapy
Pharmacogenetics
Polymorphism, Genetic
/ genetics
Receptors, Serotonin, 5-HT3
/ drug effects
Serotonin 5-HT3 Receptor Antagonists
/ therapeutic use
Vomiting
/ chemically induced
Antiemetics
Antineoplastic agents
Genetic polymorphism
Meta-analysis
Nausea
Neoplasms
Vomiting
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
27
10
2019
accepted:
09
03
2020
pubmed:
8
4
2020
medline:
10
5
2020
entrez:
8
4
2020
Statut:
ppublish
Résumé
A substantial proportion of cancer patients experience chemotherapy-induced nausea and vomiting (CINV) despite the use of antiemetic drugs. Prevalent genetic polymorphisms involved in antiemetic drug metabolism, drug transport and receptor pathways likely affect the effectiveness of antiemetics. Knowledge on which polymorphisms to integrate into individualised clinical care is needed. We did a systematic review evaluating the association between polymorphisms and effectiveness of antiemetics in cancer patients receiving moderately to highly emetogenic chemotherapy. Twenty studies n = 2331 evaluated eight polymorphisms in five candidate genes involved in 5-HT
Identifiants
pubmed: 32259776
pii: S1040-8428(20)30077-9
doi: 10.1016/j.critrevonc.2020.102939
pii:
doi:
Substances chimiques
Antiemetics
0
Antineoplastic Agents
0
Receptors, Serotonin, 5-HT3
0
Serotonin 5-HT3 Receptor Antagonists
0
Cytochrome P-450 Enzyme System
9035-51-2
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102939Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. TSUJI reports personal fees from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd. and Nippon Kayaku Co., Ltd., outside the work of this manuscript.